3 glp 1 drugs Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care Companies are racing to improve
Description
What should consumers know about the current regulatory environment
The dual combination of them did not manage to differ statistically from the usage of retatrutide alone
Gallwitz, Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes, Diabetes Metab
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
However, patients also taking insulin or sulfonylureas should monitor blood glucose carefully, as reduced carbohydrate intake may necessitate medication adjustments to prevent hypoglycaemia
10.1530/ec-23-0284 19
